Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.

Author: Yokree Yojora
Country: Cameroon
Language: English (Spanish)
Genre: Music
Published (Last): 27 May 2013
Pages: 112
PDF File Size: 8.34 Mb
ePub File Size: 10.81 Mb
ISBN: 655-8-68308-422-1
Downloads: 61409
Price: Free* [*Free Regsitration Required]
Uploader: Fenos

Now, Piramal on its own has that opportunity. Several other deals occurred over the past one year. By comparison, Cipla trades at about 4.

Country Garden, one of the largest piramwl most successful vertically integrated real estate[…]. As a global MNC, Abbott does. My Saved Articles Sign in Sign up.

Abbott to pay 17K crore for Piramal generics business

The Abbott-Piramal combine reports to him, but he notes it will be run as a standalone business unit after the merger takes effect later this year. Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and pay down debt. Based in Abbott Park, Ill. Find this comment offensive?

Disagreements over valuation have prevented more deals from getting done. India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon.

This will alert our moderators to take action Name Reason for reporting: It is paying roughly 8.

Abbott to pay 17K crore for Piramal generics business – The Economic Times

All the same, the West continues to dominate pharmaceutical innovation, and companies in India and other emerging markets could play a supportive role, according to Danzon. However, companies like Abbott and others getting into new generic drug markets must be watchful of the changing lay of the land there as well, according to Danzon.


That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing.

Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western and emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business India. The Thomson Reuters Trust Principles.

But that is also changing, she says. Its other businesses include third-party manufacturing and pathology laboratories. At the same time, hopes have receded of a wholly Indian pharmaceutical major emerging as a global player. Food and Drug Administration charged the Indian company with numerous violations on quality and safety fronts, and banned some of its piraal.

A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?

Of its brands sold on Friday, at least 48 have sales of more than Rs 10 crore a year and are marketed by a sales force of 4, who reach more than 2. Chaudhuri acknowledges those new realities, but with a patriotic tinge. But new Wharton research provides better insight into the benefits of PE buyouts.

The materialisation of this deal will also encourage buyers loosen their wallets. You have to create a whole organization, and that takes time.

Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes.

There is intense speculation that Mr Piramal will buy companies in some of these segments. Industry forecaster IMS Health predicts leading emerging markets will show annual pharmaceuticals sales growth of 14 to 17 percent throughagainst just 3 to 6 percent a year for developed markets.

It makes a lot of sense if they can pull off all the integration issues.

BOthe U. Valkation the past few years, they have realized that those pipelines are running dry, and are trying to diversify. Yet, Piramal investors are disappointed. Indian companies can hope to become truly global pharmaceutical companies only through drug discovery, says Piramal. There are a limited number of Indian generics companies that are attractive, and there might be considerable competition for them. To see your saved stories, click on link hightlighted in bold. Food and Drug Administration said in February Ranbaxy sold misbranded or adulterated drugs in the United States, valuatikn largest market, having earlier banned imports of over 30 generic drugs from the firm.


Piramal Healthcare will retain its contract manufacturing, critical care, over-the-counter drugs — all of which cumulatively generate Rs 1,crore revenues, but where margins are much lower. Some said prices of medicines will go up. Globally, Abbott also faces the pressure of playing catch-up with its bigger rivals. Danzon points to Dr.

This is no different for Chinese firms. Abbott plans to fund the deal with cash on its balance sheet and said it would not change its earnings outlook for Get instant notifications from Economic Times Allow Not now You can switch off notifications anytime using browser settings. Fill in your details: Read more on Piramal. Abbott said it was advised by Morgan Stanley, while Piramal said it did not have a financial advisor on the deal.

It will, however, continue research in drug discovery through an affiliate company. The stigma of selling—that has been holding back promoters of Indian pharmaceutical companies—is gone after two large lucrative deals in the sector, said an investment banker who asked not to be named.

BOas global drugmakers look to boost their presence in emerging markets. Choose your reason below and click on the Report button. Wharton management professor Saikat Chaudhuri says the relatively higher valuation makes sense for Abbott.